Hermetica Superfood Encyclopedia
The Short Answer
Virola spp. contain tryptamine alkaloids (DMT, 5-MeO-DMT), trimethoxystilbenes, phenolic acids, flavonoids, and monoterpene-rich essential oils that act through antiproliferative, antioxidant, and membrane-disrupting mechanisms. The trimethoxystilbene (Z)-3,5,4′-trimethoxystilbene from V. elongata inhibits Caco-2 colon cancer cell proliferation by 80% at 0.3 µM and completely at 0.4 µM in vitro, making it approximately 100-fold more potent than resveratrol under equivalent assay conditions.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordVirola spp. benefits
Virola — botanical close-up
Health Benefits
**Antiproliferative Activity**: (Z)-3,5,4′-trimethoxystilbene isolated from V
elongata bark inhibits Caco-2 colon cancer cell growth with an IC50 of 0.25 µM, roughly 100-fold more potent than the parent compound resveratrol (IC50 ~25 µM), suggesting enhanced stilbene-mediated cell cycle disruption in vitro.
**Antioxidant Effects**: V
venosa bark and leaf methanolic extracts containing ferulic acid, gallic acid, quercetin, and kaempferol demonstrate significant free radical scavenging activity; ferulic acid is identified as the primary driver of both antioxidant capacity and α-glucosidase inhibition in these extracts.
**Anti-inflammatory Action**: V
oleifera resin (>50 µg/mL) suppresses LPS-induced superoxide anion production in monocyte/macrophage cell models by 35–50% (p < 0.05), indicating reactive oxygen species scavenging and macrophage-mediated inflammatory pathway modulation.
**Topical Antifungal and Wound Healing**: V
oleifera resin formulated as a 5% cream has been investigated in rat pilot studies for wound healing and antifungal applications, with acceptable dermal tolerance and no significant changes in hepatic (ALT, AST) or renal (urea) biomarkers at this concentration.
**Antimicrobial Potential**: Essential oils from V
surinamensis, dominated by α-pinene (>33%) and β-pinene (>13%), exhibit low minimum inhibitory concentrations against select bacterial strains, with in silico modeling suggesting membrane-disruptive mechanisms linked to monoterpene lipophilicity.
**Alpha-Glucosidase Inhibition**: V
venosa methanolic extracts inhibit α-glucosidase enzyme activity in preclinical assays, an effect attributed primarily to ferulic acid and quercetin content, suggesting a potential mechanism relevant to postprandial glucose modulation, though no human data exist.
**Cytotoxic Sesquiterpene Activity**
Leaf essential oils containing (E,E)-α-farnesene (26.65–37.43%) and (E)-caryophyllene (15.7–21.4%) display cytotoxic activity in Artemia salina brine shrimp assays (LC50: 57.62–74.72 µg/mL), correlated with germacrene D content and indicative of general cytotoxic potential warranting further mechanistic study.
Origin & History
Natural habitat
Virola spp. are a genus of approximately 60 trees and shrubs in the family Myristicaceae, native to tropical rainforests of Central and South America, with highest biodiversity in the Amazon Basin, the Guianas, and western Colombia. They thrive in lowland humid forest, seasonally flooded várzea, and terra firme soils at elevations typically below 1,000 m, where they grow as medium to large canopy trees. Several species including V. elongata, V. sebifera, V. surinamensis, and V. oleifera are regionally harvested by indigenous communities for their resin, bark, and seeds, with no systematic commercial cultivation documented.
“Virola species occupy a central place in Amazonian shamanic traditions, most notably among the Yanomami, Waorani, Tukano, and related Amazonian peoples who prepare hallucinogenic snuffs called 'yakee,' 'paricá,' or 'epená' from the dried inner bark resin of V. elongata and V. theiodora, which contain significant concentrations of DMT and 5-methoxy-DMT used for ritual healing, divination, and spirit communication. The ethnobotanist Richard Evans Schultes extensively documented these preparations in the mid-20th century, establishing Virola as one of the primary botanical sources of tryptamine-based entheogenic snuffs in the neotropics and distinguishing them chemically from Anadenanthera-based snuffs. Beyond psychoactive use, bark decoctions and resins from V. sebifera, V. venosa, and V. oleifera have been employed in indigenous South American communities for wound healing, ulcer treatment, skin infections, and inflammatory conditions, with preparations applied both topically and, less commonly, as oral infusions. The seeds of V. surinamensis yield 'ucuuba fat,' a lauric-acid-rich tallow historically used in Amazonian and Northeastern Brazilian communities for soap-making, candle production, and topical skin treatments.”Traditional Medicine
Scientific Research
All published evidence for Virola spp. bioactivity derives exclusively from in vitro cell-based assays, essential oil cytotoxicity bioassays (Artemia salina), and a single small-animal pilot study using V. oleifera resin cream; no controlled human clinical trials have been registered or published as of current available data. The antiproliferative data for (Z)-3,5,4′-trimethoxystilbene (IC50 0.25 µM, Caco-2 cells) and the anti-inflammatory data for V. oleifera resin (35–50% superoxide reduction at >50 µg/mL) represent the most mechanistically detailed preclinical findings, though neither has advanced to animal xenograft models or phase I human studies. The V. oleifera rat pilot study evaluating a 5% topical resin cream reported no significant hepatic or renal toxicity markers on days 0 and 10, but the study lacked controls for wound-healing endpoints, statistical power calculation, or histopathological analysis beyond serum chemistry. Collectively, the evidence base is preclinical and fragmented across multiple species without cross-species standardization, making it impossible to generalize findings or establish dose-response relationships applicable to human supplementation.
Preparation & Dosage
Traditional preparation
**Hydroethanolic Stem Bark Extract (V. elongata)**
Used in research at concentrations yielding 14.6% total phenolics (50% flavonoids); no human supplemental dose established; typical preclinical extraction ratio not standardized for commercial use.
**Methanolic Bark/Leaf Extract (V. venosa)**
Research preparations used for antioxidant and α-glucosidase inhibition studies; no defined effective human dose; ferulic acid and quercetin content vary by harvest conditions.
**Essential Oil via Hydrodistillation (V. surinamensis, unspecified spp.)**
Characterized for antimicrobial and cytotoxic activity; no safe topical or inhalation dose established for humans; brine shrimp LC50 data (57–75 µg/mL) signal potential cytotoxicity at higher concentrations.
**Topical Resin Cream (V. oleifera, ≤5%)**
Pilot-tested in rats at 5% concentration; concentrations above 5% destabilize cream formulation due to amphoteric resin constituents; no human clinical dosing established.
**Traditional Hallucinogenic Snuff (V. elongata, V. theiodora)**
Dried and powdered inner bark resin insufflated by Amazonian shamans; contains DMT and 5-MeO-DMT; no safe or standardized dose exists and this use carries substantial psychoactive and toxicological risk.
**Seed Fat (V. surinamensis — 'Ucuuba butter')**
Used in soap, candle, and traditional topical applications; not standardized as a supplement.
**Note**
No form of Virola spp. has an established evidence-based supplemental dose for human internal use.
Nutritional Profile
Virola spp. are not consumed as dietary food sources and possess no documented macronutrient or micronutrient profile relevant to nutrition. Phytochemically, stem bark hydroethanolic extracts of V. elongata contain approximately 14.6% total phenolic compounds (with ~50% being flavonoids), including identifiable compounds such as gallic acid, catechin, and rutin. V. venosa bark and leaf extracts contain phenolic acids (ferulic acid, gallic acid, p-coumaric acid) and flavonoids (quercetin, quercetrin, kaempferol, catechin), with ferulic acid representing the dominant bioactive fraction. Leaf essential oils contribute terpenoids including (E,E)-α-farnesene (26–37%), (E)-caryophyllene (16–21%), germacrene D (~7.7%), and α-pinene (up to 33% in V. surinamensis); V. sebifera leaf extracts contain lignans (kusunokinin, hinokinin) and catechol. No bioavailability data for any Virola phytochemical in humans has been published, and the tryptamine alkaloids (DMT, 5-MeO-DMT) present in resin are rapidly metabolized by MAO enzymes when ingested orally without monoamine oxidase inhibitor co-administration.
How It Works
Mechanism of Action
The trimethoxystilbene (Z)-3,5,4′-trimethoxystilbene from V. elongata inhibits tumor cell proliferation at sub-micromolar concentrations (IC50 0.25 µM against Caco-2), likely through stilbene-mediated disruption of microtubule dynamics and cell cycle arrest analogous to combretastatin analogs, though the precise molecular target has not been confirmed in published studies. V. oleifera resin components scavenge reactive oxygen species in macrophage models, reducing LPS-stimulated superoxide anion production by 35–50%, suggesting interference with NADPH oxidase activation or direct radical quenching by phenolic constituents. Phenolic acids (ferulic acid, gallic acid, p-coumaric acid) and flavonoids (quercetin, kaempferol, catechin) from V. venosa inhibit α-glucosidase through competitive or mixed-mode enzyme inhibition and donate hydrogen atoms to neutralize DPPH and ABTS radicals, a dual mechanism common to polyphenol-rich extracts. Essential oil monoterpenes (α-pinene, β-pinene, limonene) and sesquiterpenes ((E)-caryophyllene, germacrene D) exert antimicrobial effects through predicted membrane lipid bilayer perturbation and nonspecific cytotoxicity, consistent with the brine shrimp LC50 values of 57–75 µg/mL recorded across Virola leaf oil specimens.
Clinical Evidence
No clinical trials in human subjects have been conducted on any Virola species preparation for any indication. The totality of medicinal evidence consists of in vitro cell line experiments (Caco-2, monocyte/macrophage models), brine shrimp toxicity assays, and one small rat pilot study of a topical formulation. Effect sizes reported in cell-based models are compelling at the in vitro level—particularly the 100-fold potency advantage of V. elongata trimethoxystilbene over resveratrol—but in vitro potency does not reliably predict in vivo or clinical efficacy. Confidence in any therapeutic claim for human use must be rated as very low, consistent with an evidence tier of Preliminary.
Safety & Interactions
Virola leaf essential oils exhibit cytotoxicity in Artemia salina brine shrimp assays at LC50 values of 57.62–74.72 µg/mL, correlated with germacrene D content, indicating concentration-dependent toxicity that warrants caution in any topical or internal human application. The tryptamine alkaloids DMT and 5-MeO-DMT present in Virola resin are potent psychoactive serotonergic agonists acting at 5-HT2A receptors; their use carries risks of severe psychological distress, cardiovascular stimulation, and life-threatening serotonin syndrome if combined with monoamine oxidase inhibitors, SSRIs, SNRIs, tricyclic antidepressants, or other serotonergic agents. Topical V. oleifera resin at 5% in rat pilot studies produced no significant hepatotoxic or nephrotoxic changes (ALT, AST, urea unchanged; p > 0.05), but no human safety data exist, and concentrations exceeding 5% are physically unstable in cream formulations. No data are available regarding safe use during pregnancy or lactation, pediatric safety, or long-term toxicological profiles; pregnant individuals and those with cardiovascular, hepatic, renal, or psychiatric conditions should avoid all Virola preparations pending adequate human safety studies.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
ucuubayakeeVirola spp.Virola sebiferaVirola elongataMyristicaceae resin treeparicáVirola theiodoraepenáVirola surinamensisVirola (Virola theiodora)Virola venosaVirola oleifera
Frequently Asked Questions
What psychoactive compounds are found in Virola and how are they used traditionally?
Virola species, particularly V. elongata and V. theiodora, contain tryptamine alkaloids including DMT (N,N-dimethyltryptamine) and 5-methoxy-DMT concentrated in the inner bark resin, which are prepared by Amazonian indigenous peoples (Yanomami, Waorani) as hallucinogenic insufflation powders called yakee, paricá, or epená. These snuffs are blown into the nasal passages during shamanic healing and divination ceremonies, producing rapid and intense psychedelic effects due to direct nasal mucosa absorption bypassing first-pass hepatic MAO metabolism. This use carries significant psychological and cardiovascular risks, and Virola-derived DMT preparations are controlled substances in many jurisdictions.
Is Virola oleifera resin safe for topical use?
A rat pilot study evaluating a 5% V. oleifera resin cream on days 0 and 10 found no statistically significant changes in liver enzymes (ALT, AST) or renal urea levels compared to controls (p > 0.05), suggesting low systemic toxicity at this concentration in the animal model. However, concentrations above 5% destabilize cream formulations due to amphoteric substances in the resin, and no controlled human safety or efficacy trials have been published. Until human clinical data are available, topical use should be considered experimental with cautious application.
How potent is Virola elongata's anticancer compound compared to resveratrol?
The trimethoxystilbene (Z)-3,5,4′-trimethoxystilbene isolated from V. elongata bark inhibits Caco-2 human colon cancer cell growth in vitro with an IC50 of 0.25 µM, achieving 80% growth inhibition at 0.3 µM and complete inhibition at 0.4 µM. This is approximately 100-fold more potent than resveratrol, which achieves only about 70% Caco-2 growth inhibition at 25 µM under comparable assay conditions. These results are from cell-line studies only; no animal or human anticancer data have been generated, and in vitro potency does not guarantee clinical relevance.
What are the main chemical compounds in Virola essential oils?
Virola leaf essential oils obtained by hydrodistillation are dominated by sesquiterpenes and monoterpenes: (E,E)-α-farnesene constitutes 26.65–37.43%, (E)-caryophyllene 15.7–21.4%, germacrene D approximately 7.72%, and α-pinene up to 16.91% depending on species. V. surinamensis essential oil is notably monoterpene-rich, with α-pinene exceeding 33%, β-pinene above 13%, and limonene and myrcene as additional major constituents. These terpene profiles contribute to the antimicrobial and cytotoxic activities documented in preclinical assays, including brine shrimp LC50 values of 57–75 µg/mL linked to germacrene D content.
Are there any clinical trials supporting Virola medicinal use?
As of currently available published data, no human clinical trials have been conducted for any Virola species preparation or extract for any medical indication. All evidence is confined to in vitro cell line experiments, brine shrimp cytotoxicity assays, and a single small rat pilot study evaluating a topical V. oleifera resin cream for dermal safety. Researchers and consumers should treat all potential health benefits as preliminary and unvalidated in humans, and no evidence-based dosing recommendations can be made for medicinal supplementation.
What is the difference between Virola bark extract and Virola essential oil for health benefits?
Virola bark extracts, particularly methanolic extracts, concentrate antiproliferative stilbenes like (Z)-3,5,4′-trimethoxystilbene and antioxidant compounds, making them more relevant for cell-protective research. Virola essential oils contain different volatile chemical constituents that have been traditionally used but lack the same in vitro antiproliferative potency demonstrated in bark preparations. The choice between these forms depends on whether the intended benefit is antioxidant support (essential oil) or cell-cycle-related research application (bark extract).
Can Virola supplements be used alongside antioxidant medications or cancer treatments?
Because Virola bark contains potent antiproliferative compounds that disrupt cell cycle in vitro, concurrent use with cancer medications or certain antioxidant therapies should only occur under medical supervision to avoid unpredictable interactions. Virola's stilbene compounds may theoretically potentiate or interfere with chemotherapy mechanisms, though human clinical data are lacking. Anyone taking prescription medications, especially cancer therapies or anticoagulants, should consult their healthcare provider before Virola supplementation.
Why is Virola elongata specifically studied compared to other Virola species?
Virola elongata bark has been the focus of anticancer research because it yields (Z)-3,5,4′-trimethoxystilbene, a stilbene derivative approximately 100-fold more potent than resveratrol in inhibiting colon cancer cell growth (IC50 0.25 µM vs 25 µM). This exceptional in vitro potency distinguishes V. elongata from other Virola species and makes it a priority for phytochemical and mechanism-of-action studies. However, this in vitro data has not yet translated into clinical trials in humans, limiting practical recommendations for supplementation.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w virola-virola-spp curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
